Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic
In a significant development for global health preparedness, RedHill Biopharma Ltd. has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to advance opaganib, a promising treatment for Ebola virus disease (EBOV). This collaboration marks a crucial step in combating
The biopharmaceutical industry is persistently advancing, fueled by innovations and strategic alliances designed to tackle some of the toughest medical challenges. A particularly promising collaboration that has emerged is the partnership between Matica Biotechnology Inc. (Matica Bio) and
The approval of Bluebird bio's gene therapy, Skysona, in September 2022 by the FDA marked a significant milestone for treating cerebral adrenoleukodystrophy (CALD), a rare and fatal childhood brain disorder. Skysona's innovation generated hope for families dealing with CALD, yet recent developments
In a dynamic twist within the pharmaceutical industry, several companies are locked in a fierce race to develop the next generation of obesity drugs. As the battle heats up, each aims to outdo the other, with innovations that promise to revolutionize the way obesity is treated. This race isn't just
The biopharmaceutical industry is rapidly evolving, fueled by cutting-edge technologies and scientific breakthroughs. Novel treatments such as cell and gene therapies, biologics, and vaccines are reaching the market at unprecedented speeds. However, the rigorous journey from drug development to